Physician profile
Bahar Bastani
NPI 1326059957
$87,262.19
in general payments reported to CMS, 2019-2025
16 companies · $9,503 in 2025
The $9,503 reported for 2025 was more than what 95% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $10K · 2021: $2,883 · 2022: $6,686 · 2023: $38K · 2024: $20K · 2025: $9,503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Travel and Lodging: $14K · Honoraria: $9,450 · Consulting Fee: $6,650 · Food and Beverage: $4,839 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $600 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,450.00 |
| Travel and Lodging | $13,927.57 |
| Honoraria | $9,450.00 |
| Consulting Fee | $6,650.00 |
| Food and Beverage | $4,839.43 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $600.00 |
| Education | $129.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $48,739.03 | 2023-2025 | Filspari, Thiola |
| Horizon Therapeutics Plc | $15,778.09 | 2020-2023 | Procysbi |
| Alnylam Pharmaceuticals INC. | $10,589.00 | 2020-2025 | Oxlumo |
| Amgen INC. | $5,916.07 | 2024-2025 | Procysbi, Evenity |
| Calliditas Therapeutics US INC. | $4,755.18 | 2023-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $548.58 | 2020-2025 | Terlivaz |
| Otsuka America Pharmaceutical, INC. | $234.21 | 2019-2025 | Jynarque |
| Novo Nordisk INC | $142.12 | 2024 | Rivfloza |
| Genzyme Corporation | $125.00 | 2020 | |
| Novo Nordisk Health Care Ag | $122.83 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $116.33 | 2025 | |
| Aurinia Pharma U.S., INC. | $89.57 | 2024 | Lupkynis |
| Glaxosmithkline, LLC. | $35.93 | 2023 | |
| Lundbeck LLC | $31.28 | 2019 | |
| Vifor Pharma, INC. | $20.12 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.85 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bahar Bastani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.